Skip to main content

Table 1 Summary of the study outcome and measures

From: Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial

Primary endpoint

 Change in PMR in the primary lesion measured by CMR imaging

Secondary endpoint

 Change in PMR in all lesions measured by CMR imaging

 Percentage change in PMR in the primary lesion measured by CMR imaging

 Percentage change in PMR in all lesion measured by CMR imaging

 Changes in Hounsfield units, plaque volume, vessel area, and plaque area in the primary lesion measured by CTA

 Changes in Hounsfield units, plaque volume, vessel area, and plaque area in all lesions measured by CTA

 Percentage changes in Hounsfield units, plaque volume, vessel area, and plaque area in the primary lesion measured by CTA

 Percentage changes in Hounsfield units, plaque volume, vessel area, and plaque area in all lesions measured by CTA

Other endpoint

 Changes and percentage changes in triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol, non-HDL-cholesterol, VLDL-cholesterol, remnant-like cholesterol, LPL activity, and high-sensitivity C-reactive protein

 Changes and percentage changes in small, dense LDL and mean LDL particle diameter

 Changes and percentage changes in EPA, DHA, AA, EPA/AA ratio, and omega-3 index (weight percentage of eicosapentaenoic acid [EPA, C20:5ω3] and docosahexaenoic acid [DHA, C20:6ω3] in total fatty acids out of all lipids)

 Changes and percentage changes in leptin and adiponectin

  1. AA arachidonic acid, CMR cardiac magnetic resonance, CTA computed tomography angiography, HDL high-density lipoprotein, LDL low-density lipoprotein, LPL lipoprotein lipase, PMR plaque-to-myocardium signal intensity ratio, VLDL very-low density lipoprotein
Back to article page

Trials

ISSN: 1745-6215